TD Cowen Raises Revvity (RVTY) Price Target to $175

TD Cowen has reiterated its Buy rating on Revvity, Inc. (NYSE: RVTY) and raised its price target to $175 from a prior target of $130. This update came on October 13, 2026, as part of the firm's ongoing coverage of the healthcare diagnostics company.

TD Cowen's Call on Revvity

TD Cowen's new target of $175 reflects a positive outlook for Revvity, though the stock was recently trading at $153.35, which is about 12.4% below the target. The firm maintains a bullish stance, suggesting confidence in Revvity's business performance and growth potential.

Other Institutional Activity in Revvity

Several institutional investors have adjusted their positions in Revvity recently. T. Rowe Price Investment Management, Inc. reduced its stake by 3,938,163 shares, ending with 18,261,177 shares worth approximately $2.79 billion. Meanwhile, Jupiter Topco LLC saw a significant increase, adding 4,318,807 shares for a total of 8,637,614 shares valued at about $1.32 billion. Edgepoint Investment Group Inc. trimmed its holdings by 256,097 shares, now holding 8,544,479 shares worth around $1.30 billion. Blackrock Inc. increased its position slightly, adding 408,185 shares for a total of 7,658,369 shares valued at about $1.17 billion. Vanguard Capital Management LLC made a minor reduction, holding 7,300,973 shares worth approximately $1.11 billion after decreasing its stake by 29,321 shares.

Revvity, Inc. Stock Up 6.9%

Revvity's stock is currently trading around $153.35. While this price is below TD Cowen's new target of $175, it indicates a potential upside for investors. The stock's performance is also noteworthy as it reflects the company's solid revenue generation and growth strategy in the diagnostics sector.

Recent Earnings

Revvity reported trailing twelve-month revenue of approximately $2.91 billion, with a net margin of 8.2%. Its next earnings report is scheduled for October 26, 2026, which will provide further insights into the company’s financial health and growth prospects.

Insider Buying and Selling at Revvity, Inc.

Recent insider transactions include Miriame Victor, an officer, who sold 1,862 shares at an average price of $97.13 on February 24, 2026, totaling about $180,856. Anita Gonzales, also an officer, sold 80 shares at $92.80 on April 20, 2026, for a total of $7,424, and another 85 shares at $109.48 on July 20, 2026, amounting to $9,306. Maxwell Krakowiak, the Chief Financial Officer, sold 1,631 shares at $144.53 on September 21, 2026, for a total value of $235,728. These sales were not part of planned transactions and occurred before the recent analyst call.

Analysts Set New Price Targets

On October 13, 2026, TD Cowen maintained its Buy rating on Revvity with a target price of $175. Earlier, on September 1, 2026, RBC Capital initiated coverage with a Sector Perform rating and a target of $135. Keybanc maintained an Overweight rating on September 4, 2026, raising its target to $165 from $125. Barclays also maintained its Equal-Weight rating with a revised target of $160 on October 7, 2026. The consensus rating from analysts reflects a generally positive outlook on Revvity's performance, with a mean target price suggesting further upside potential.

About Revvity

Revvity, Inc. is a healthcare technology company based in Waltham, MA, specializing in health sciences solutions and diagnostics. The firm offers a range of products, including instruments and software for early detection of various health conditions. With a workforce of about 11,000 employees, Revvity plays a significant role in the diagnostics and research industry, making it a key player in healthcare innovation.

Bottom Line

Investors should keep an eye on Revvity's upcoming earnings release on October 26, 2026. Analysts remain optimistic about the company's future, as reflected in TD Cowen's recent rating adjustments. With shares currently trading below the new target, there may be opportunities for growth in the coming months.